| A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours G Mak, JC Soria, SP Blagden, R Plummer, RA Fleming, N Nebot, J Zhang, ... British journal of cancer 120 (10), 975-981, 2019 | 66 | 2019 |
| Dynamics of neutrophils-to-lymphocyte ratio predict outcomes of PD-1/PD-L1 blockade M Moschetta, M Uccello, B Kasenda, G Mak, A McClelland, S Boussios, ... BioMed research international 2017, 2017 | 54 | 2017 |
| Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with … S Senan, I Okamoto, G Lee, Y Chen, S Niho, G Mak, W Yao, N Shire, ... Clinical lung cancer 21 (2), e84-e88, 2020 | 53 | 2020 |
| Prospective analysis of 895 patients on a UK Genomics Review Board DA Moore, M Kushnir, G Mak, H Winter, T Curiel, M Voskoboynik, ... ESMO open 4 (2), e000469, 2019 | 27 | 2019 |
| Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma L Goyal, HT Arkenau, B Tran, JC Soria, R Bahleda, G Mak, A Zhu, M Javle, ... Annals of Oncology 28, iii145, 2017 | 25 | 2017 |
| Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation G Mak, M Chin, N Nahar, P De Souza BMC research notes 7, 1-4, 2014 | 21 | 2014 |
| The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: an Australian population-based multicenter study EY He, NJ Hawkins, G Mak, F Roncolato, D Goldstein, W Liauw, ... The oncologist 21 (5), 618-625, 2016 | 18 | 2016 |
| Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA) M Uccello, M Moschetta, G Mak, T Alam, CM Henriquez, HT Arkenau Current Oncology 25 (1), 90-94, 2018 | 13 | 2018 |
| ADRIATIC: A phase III trial of durvalumab±tremelimumab after concurrent chemoradiation for patients with limited stage small cell lung cancer S Senan, N Shire, G Mak, W Yao, H Jiang Annals of Oncology 30, ii25, 2019 | 12 | 2019 |
| Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours N Nebot, HT Arkenau, JR Infante, JC Chandler, A Weickhardt, JD Lickliter, ... British journal of clinical pharmacology 84 (4), 764-775, 2018 | 12 | 2018 |
| Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment G Mak, HT Arkenau, M Chin Melanoma Research 24 (4), 408-412, 2014 | 10 | 2014 |
| A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. HT Arkenau, A Gazzah, R Plummer, SP Blagden, G Mak, JC Soria, ... Journal of Clinical Oncology 33 (15_suppl), 2593-2593, 2015 | 8 | 2015 |
| An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours HT Arkenau, A Italiano, G Mak, M Toulmonde, RD Baird, ... European Journal of Cancer 103, 17-23, 2018 | 7 | 2018 |
| Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer M Moschetta, G Mak, J Hauser, C Davies, M Uccello, HT Arkenau Experimental Hematology & Oncology 6, 1-5, 2017 | 5 | 2017 |
| Use of neostigmine in capecitabine-induced paralytic ileus G Mak, R Ward, Y Shehabi, R Venkateswaran, M Chin Tumori Journal 99 (5), e225-e228, 2013 | 5 | 2013 |
| Long survival (cure) to cisplatin/Infusional 5-Flurouracil in metastatic squamous cell anal cancer with extensive liver and lung metastases A Haydon, R Tay, G Mak, J Shapiro Case Reports in Clinical Medicine 4 (03), 73, 2015 | 3 | 2015 |
| TROPION-Lung04: Phase 1b, multicenter study of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy±carboplatin in advanced/metastatic non-small cell lung cancer … H Borghaei, SN Waqar, DS Bruno, S Kitazono, K Wakuda, AI Spira, ... Journal of Clinical Oncology 41 (16_suppl), TPS3158-TPS3158, 2023 | 2 | 2023 |
| Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab±Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04 KP Papadopoulos, D Bruno, S Kitazono, S Murakami, M Gutierrez, ... ELSEVIER SCIENCE INC, 2023 | 2 | 2023 |
| Dynamics of neutrophil to lymphocyte ratio (NLR) predict effectiveness of PD1/PDL1 inhibition M Moschetta, B Kasenda, G Mak, M Voskoboynik, N Martynyuk, S Rafii, ... Annals of Oncology 27, vi24, 2016 | 2 | 2016 |
| Immunotherapy in colorectal cancer G Mak, M Moschetta, HT Arkenau Colorectal cancer: from pathogenesis to treatment 301, 2016 | 2 | 2016 |
